Author

Mahmoud S. Elkotamy

h-index 10 View on Semantic Scholar

We have 3 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2/c-MET antagonists.

Chemical 8b may serve as a promising candidate for further anticancer research after demonstrating encouraging dual kinase inhibitory action and exhibiting a favorable selectivity profile for normal MCF-10A cells.

Mohamed El-Naggar, Rofaida Salem, Mona M. Kabeel et al. · Bioorganic & Medicinal Chemi... · 0 citations

Open access Aug 2026

1-Butylindoline-2,3-dione derivatives as potent VEGFR-2 inhibitors: synthesis, mechanistic anticancer studies, and molecular dynamics simulations

Compound 6b is identified as a promising lead candidate for further development as a VEGFR-2-targeted anticancer agent and stable backbone behavior, regulated ligand fluctuations, preserved structural compactness, and sustained hydrogen bonding within the 6b-VEGFR-2 complex are identified.

Mohamed El-Naggar, Hend I Abdelaal, Mohamed E Albakri et al. · RSC Advances · 0 citations

Open access Jul 2026

In silico pipeline for GSK 3β inhibitor discovery in Alzheimer’s disease using pharmacophore screening, docking, ADME filtering, and MD validation

These findings identify SB1 and LB1 as promising, safe, and brain-penetrant GSK-3β lead compounds for experimental validation in Alzheimer’s disease.

Mahmoud S. Elkotamy, Mohamed K. Elgohary, Ahmed S. Alkotami et al. · Scientific Reports · 0 citations